Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (NCT07169617) titled 'Testing the SurVaxM Vaccine for Lung Cancer Prevention' on Sept. 11.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Prevention. Masking: None (Open Label).
Primary Sponsor: National Cancer Institute (NCI)
Condition:
Lung Carcinoma
Intervention:
Procedure: Biospecimen Collection
Drug: Montanide ISA 51 VG
Other: Questionnaire Administration
Biological: Sargramostim
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: February 25, 2026
Target Sample Size: 80
Countries of Recruitment:
United States
To know mor...